Erasca (ERAS) risk factors, FY2025 10-K

Risks related to our limited operating history, financial position and need for additional capital

1. 01We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it
2. 02We will require substantial additional capital to finance our operations, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations25% rewritten
3. 03costs associated with any products or technologies that we may in-license or acquire
4. 04Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
5. 05Our portfolio of investments or bank deposits may be subject to market, interest and credit risk that may reduce their value and adversely affect our business, results of operations and financial condition

Risks related to the discovery, development and regulatory approval of our product candidates

1. 06If we are unable to successfully develop, obtain regulatory approval and ultimately commercialize any of our current or future product candidates, or experience significant delays in doing so, our business will be materially harmed
2. 07Our scientific approach to the discovery and development of product candidates is unproven, and we do not know whether we will be able to develop any products of commercial value, or if competing approaches will limit the commercial value of our product candidates
3. 08If any of these events occur, we may be forced to delay, modify, or abandon our development efforts for a program or programs, which would have a material adverse effect on our business and could potentially cause us to cease operations26% rewritten
4. 09us, to conduct additional preclinical studies or clinical trials, which would cause us to incur additional operating expenses and delays and may not be sufficient to support regulatory approval on a timely basis or at allNew
5. 10Any difficulties or delays in the commencement or completion, or termination or suspension, of our current or future clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects
6. 11third parties being unwilling or unable to satisfy their contractual obligations to us in a timely manner
7. 12We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling subjects in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected
8. 13our reputation may suffer
9. 14As an organization, we may be unable to complete clinical trials for any of our product candidates
10. 15We intend to develop our product candidates in combination with other therapies, which exposes us to additional risks
11. 16The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed
12. 17such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission60% rewritten
13. 18Because we have a number of product candidates and development programs in our pipeline, we may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
14. 19We may not be able to obtain or maintain orphan designations for any of our product candidates, and we may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity60% rewritten
15. 20We have previously and may in the future conduct certain of our clinical trials for our product candidates outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our businessNew
16. 21Interim, topline and preliminary data from our clinical trials and preclinical studies that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data27% rewritten
17. 22A Fast Track Designation may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval22% rewritten

Risks related to our reliance on third parties

1. 23in the event of approval to market and commercialize a product, an inability to meet commercial demands for such product
2. 24termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us
3. 25Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basisNew
4. 26Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
5. 27We may seek to enter into collaborations, licenses and other similar arrangements and may not be successful in doing so, and even if we are, we may relinquish valuable rights and may not realize the benefits of such relationships
6. 28Joyo’s activities in China could have a negative impact on our ability to develop and commercialize ERAS-0015New

Risks related to commercialization of our product candidates

1. 29Even if we receive regulatory approval for any product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense
2. 30The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity
3. 31The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses
4. 32Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated
5. 33The commercial success of our product candidates will depend upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community
6. 34unfavorable publicity relating to the product, our company, or product candidates or similar approved products or product candidates in development by third parties71% rewritten
7. 35The market opportunities for our product candidates may be limited to patients who are ineligible for or have failed prior treatments and may be small or different from our estimates
8. 36Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties

Risks related to our business operations and industry

1. 37Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide
2. 38future accounting pronouncements or changes in our accounting policies
3. 39Our success is dependent on our ability to attract and retain highly qualified management and other clinical and scientific personnel
4. 40We may encounter difficulties in managing our growth and expanding our operations successfully
5. 41We are subject to various US federal, state and foreign healthcare laws and regulations, which could increase compliance costs, and our failure to comply with these laws and regulations could harm our reputation, subject us to significant fines and liability or otherwise adversely affect our business
6. 42Recently enacted legislation, future legislation and healthcare reform measures may increase the difficulty and cost for us to obtain marketing approval for and commercialize our product candidates and may affect the prices we may set42% rewritten
7. 43If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products
8. 44a decline in our stock price
9. 45Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities
10. 46We and any of our current or potential future collaborators or partners will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business
11. 47Our business may be affected by the evolving regulatory framework for AI TechnologiesNew
12. 48Our business is subject to risks arising from pandemic and epidemic diseases66% rewritten
13. 49Our business could be affected by litigation, government investigations and enforcement actions
14. 50Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements
15. 51We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management
16. 52Our ability to use net operating loss carryforwards and other tax attributes may be limited
17. 53Investors’ expectations of our performance relating to environmental, social and governance factors may impose additional costs and expose us to new risks
18. 54Changes to United States tariff and import/export regulations may have a negative effect on us92% rewritten

Risks related to our intellectual property

1. 55We may not be able to protect our intellectual property and proprietary rights throughout the world21% rewritten
2. 56Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements22% rewritten
3. 57Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our products
4. 58Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad
5. 59Patent terms may be inadequate to protect our competitive position on products and product candidates for an adequate amount of time
6. 60If we do not obtain patent term extension for our product candidates, our business may be materially harmed
7. 61We may be subject to claims challenging the inventorship of our patents and other intellectual property
8. 62If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
9. 63We may be subject to claims that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property
10. 64We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products and product candidates
11. 65Third-party claims of intellectual property infringement, misappropriation or other violations against us or our collaborators may prevent or delay the development and commercialization of our product candidates
12. 66We may become involved in lawsuits to protect or enforce our owned and in-licensed patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful
13. 67If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
14. 68Intellectual property rights do not necessarily address all potential threats
15. 69the patents of others may harm our business; and
16. 70Should any of the foregoing occur, it could adversely affect our business, financial condition, results of operations and prospects
17. 71the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners
18. 72We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses26% rewritten

Risks related to ownership of our common stock

1. 73The trading price of the shares of our common stock has been, and is likely to continue to be highly volatile, and purchasers of our common stock could incur substantial losses
2. 74changes in accounting standards, policies, guidelines, interpretations or principles
3. 75An active, liquid trading market for our common stock may not be maintained
4. 76Our executive officers, directors and principal stockholders, if they choose to act together, will continue to have the ability to significantly influence all matters submitted to stockholders for approval
5. 77We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock
6. 78Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities
7. 79We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors
8. 80exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved
9. 81Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management
10. 82We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives
11. 83We are subject to US and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. We could face criminal liability and other serious consequences for violations, which could harm our business
12. 84Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences
13. 85We and any of our third-party manufacturers or suppliers may use potent chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time-consuming or costly
14. 86Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
15. 87Unstable market and economic conditions and adverse developments with respect to financial institutions and associated liquidity risk may have serious adverse consequences on our business, financial condition and stock price
16. 88Changes in tax law may materially adversely affect our financial condition, results of operations and cash flows
17. 89If securities or industry analysts do not publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline
18. 90If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline
19. 91Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
20. 92We could be subject to securities class action litigation